Tailoring recombinant protein quality by rational media design

Biotechnology Progress

Volumn 31, Issue 3, 2015, Pages 615-629

  Brühlmann, David ^a,b   Jordan, Martin ^a   Hemberger, Jürgen ^c   Sauer, Markus ^b   Stettler, Matthieu ^a   Broly, Hervé ^a  

^a MERCK SERONO S A   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c TECHNISCHE HOCHSCHULE MITTELHESSEN   (Germany)

Author keywords

Cell culture medium; Glycosylation; Mammalian; Media design; Quality attributes; Therapeutic protein

Indexed keywords

ANIMAL CELL CULTURE; CELLS; GLYCOSYLATION; MAMMALS;

CELL CULTURE MEDIUMS; LOW-MOLECULAR-WEIGHT SPECIES; MAMMALIAN; MAMMALIAN CELL CULTURE; QUALITY ATTRIBUTES; QUALITY ENGINEERING; STRUCTURAL CHARACTERISTICS; THERAPEUTIC PROTEIN;

RECOMBINANT PROTEINS;

MAMMALIA;

CULTURE MEDIUM; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CULTURE MEDIUM; GLYCOSYLATION; MAMMAL; MOLECULAR WEIGHT;

ANIMALS; CELL LINE; CULTURE MEDIA; GLYCOSYLATION; MAMMALS; MOLECULAR WEIGHT; PROTEIN AGGREGATES; RECOMBINANT PROTEINS;

EID: 84931562808     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.2089     Document Type: Article

References (163)

1. Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012;30:1158-1170.
2. Ahn W, Antoniewicz M. Towards dynamic metabolic flux analysis in CHO cell cultures. Biotechnol J. 2012;7:61-74.
3. Kantardjieff A, Zhou W. Mammalian cell cultures for biologics manufacturing. In: Advances in Biochemical Engineering/Biotechnology, 1st ed. Berlin Heidelberg: Springer-Verlag 2014;139:259 pp.
4. Wurm F. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393-1398.
5. Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. Cell culture processes for monoclonal antibody production. mAbs. 2010;2:466-479.
6. Yu M, Hu Z, Pacis E, Vijayasankaran N, Shen A, Li F. Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process. Biotechnol Bioeng. 2011;108:1078-1088.
7. Huang Y, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Prog. 2010;26:1400-1410.
8. Chugh P, Roy V. Biosimilars: current scientific and regulatory considerations. Curr Clin Pharmacol. 2014;9:53-63.
9. Bumbaca D, Boswell C, Fielder P, Khawli L. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. AAPS J. 2012;14:554-558.
10. Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008;39:113-118.
11. Jenkins N, Meleady P, Tyther R, Murphy L. Strategies for analysing and improving the expression and quality of recombinant proteins made in mammalian cells. Biotechnol Appl Biochem. 2009;53:73-83.
12. Boswell C, Tesar D, Mukhyala K, Theil F, Fielder P, Khawli L. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21:2153-2163.
13. Hossler P. Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. Adv Biochem Eng/Biotechnol. 2012;127:187-219.
14. Tsubaki M, Terashima I, Kamata K, Koga A. Cterminal modification of monoclonal antibody drugs: amidated species as a general product-related substance. Int J Biol Macromol. 2013;52:139-147.
15. Satoh M, Iida S. Non-fucosylated therapeutic antibodies as next-generation antibodies. Exp Opin Biol Ther. 2006;6:1161-1173.
16. Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharm Ther. 2008;84:548-558.
17. Khawli L, Goswami S, Hutchinson R, et al. Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs. 2010;2:613-624.
18. Butler M, Meneses-Acosta A. Recent advances in technology supporting biopharmaceutical production from mammalian cells. Appl Microbiol Biotechnol. 2012;96:885-894.
19. Kremkow B, Lee KH. Next-generation sequencing technologies and their potential impact on CHO cell-based biomanufacturing. Pharm Bioprocess. 2013;1:455-465.
20. Cromwell M, Hilario E, Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006;8:E572-E579.
21. Bhoskar P, Belongia B, Smith R, Yoon S, Carter T, Xu J. Free light chain content in culture media reflects recombinant monoclonal antibody productivity and quality. Biotechnol Prog. 2013;29:1131-1139.
22. Beck A, Reichert J. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs. 2012;4:419-425.
23. Ivarsson M, Villiger T, Morbidelli M, Soos M. Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation. J Biotechnol. 2014;188C:88-96.
24. Du Z, Treiber D, McCarter J, et al. Use of a small molecule cell cycle inhibitor to control cell growth and improve specific productivity and product quality of recombinant proteins in CHO cell cultures. Biotechnol Bioeng. 2015;112:141-155.
25. Schmelzer A, Miller W. Hyperosmotic stress and elevated pCO2 alter monoclonal antibody charge distribution and monosaccharide content. Biotechnol Prog. 2002;18:346-53.
26. Meuwly F, Weber U, Ziegler T, et al. Conversion of a CHO cell culture process from perfusion to fed-batch technology without altering product quality. J Biotechnol. 2006;123:106-116.
27. Hossler P, Khattak S, Li Z. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009;19:936-949.
28. Gramer M. Product quality considerations for mammalian cell culture process development and manufacturing. Adv Biochem Eng/Biotechnol. 2014;139:123-166.
29. Gramer M, Eckblad J, Donahue R, et al. Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng. 2011;108:1591-1602.
30. Luo J, Zhang J, Ren D, et al. Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol Bioeng. 2012;109:2306-2315.
31. Jing Y, Borys M, Nayak S, et al. Identification of cell culture conditions to control protein aggregation of IgG fusion proteins expressed in Chinese hamster ovary cells. Process Biochem. 2012;47:69-75.
32. Trexler-Schmidt M, Sargis S, Chiu J, et al. Identification and prevention of antibody disulfide bond reduction during cell culture manufacturing. Biotechnol Bioeng. 2010;106:452-461.
33. Jordan M, Stettler M, Broly H. Will we ever find a perfect medium for mammalian cell culture? Pharm Bioprocess. 2013;1:411-413.
34. Rouiller Y, Périlleux A, Vesin M, Stettler M, Jordan M, Broly H. Modulation of mAb quality attributes using microliter scale fed-batch cultures. Biotechnol Prog. 2014;30:571-583.
35. Jordan M, Voisard D, Berthoud A, et al. Cell culture medium improvement by rigorous shuffling of components using media blending. Cytotechnology. 2013;65:31-40.
36. Rouiller Y, Périlleux A, Collet N, Jordan M, Stettler M, Broly H. A high-throughput media design approach for high performance mammalian fed-batch cultures. mAbs. 2013;5:501-511.
37. Crowell C, Grampp G, Rogers G, Miller J, Scheinman R. Amino acid and manganese supplementation modulates the glycosylation state of erythropoietin in a CHO culture system. Biotechnol Bioeng. 2007;96:538-549.
38. Kaufman R, Swaroop M, Murtha-Riel P. Depletion of manganese within the secretory pathway inhibits O-linked glycosylation in mammalian cells. Biochemistry. 1994;33:9813-9819.
39. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science. 1955;122:501-514.
40. McAtee A, Templeton N, Young J. Role of Chinese hamster ovary central carbon metabolism in controlling the quality of secreted biotherapeutic proteins. Pharm Bioprocess. 2014;2:63-74.
41. Brooks S. Protein glycosylation in diverse cell systems: implications for modification and analysis of recombinant proteins. Exp Rev Proteomics. 2006;3:345-359.
42. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1999;1473:4-8.
43. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97:2426-2447.
44. Chee Furng Wong D, Tin Kam Wong K, Tang Goh L, Kiat Heng C, Gek Sim Yap M. Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. Biotechnol Bioeng. 2005;89:164-177.
45. Pacis E, Yu M, Autsen J, Bayer R, Li F. Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnol Bioeng. 2011;108:2348-2358.
46. Rouiller Y, Périlleux A, Marsaut M, Stettler M, Vesin M, Broly H. Effect of hydrocortisone on the production and glycosylation of an Fc-fusion protein in CHO cell cultures. Biotechnol Prog. 2012;28:803-813.
47. Konno Y, Kobayashi Y, Takahashi K, et al. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology. 2012;64:249-265.
48. Yang J, Ai J, Bao Y, et al. Investigation of the correlation between charge and glycosylation of IgG1 variants by liquid chromatography-mass spectrometry. Anal Biochem. 2014;448:82-91.
49. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226-234.
50. Eon-Duval A, Broly H, Gleixner R. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach. Biotechnol Prog. 2012;28:608-622.
51. Val I, Kontoravdi C, Nagy J. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. Biotechnol Prog. 2010;26:1505-1527.
52. Arnold J, Wormald M, Sim R, Rudd P, Dwek R. The impact of glycosylation on the biological function and structure of human immunoglobulins. Ann Rev Immunol. 2007;25:21-50.
53. Yuk I, Zhang B, Yang Y, et al. Controlling glycation of recombinant antibody in fed-batch cell cultures. Biotechnol Bioeng. 2011;108:2600-2610.
54. Lapolla A, Traldi P, Fedele D. Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem. 2005;38:103-115.
55. Zhuang X, Pang X, Zhang W, et al. Effects of zinc and manganese on advanced glycation end products (AGEs) formation and AGEs-mediated endothelial cell dysfunction. Life Sci. 2012;90:131-139.
56. Quan C, Alcala E, Petkovska I, et al. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal Biochem. 2008;373:179-191.
57. Nakajou K, Watanabe H, Kragh-Hansen U, Maruyama T, Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta. 2003;1623:88-97.
58. Gagnon M, Hiller G, Luan Y, Kittredge A, DeFelice J, Drapeau D. High-end pH-controlled delivery of glucose effectively suppresses lactate accumulation in CHO fed-batch cultures. Biotechnol Bioeng. 2011;108:1328-1337.
59. Jayme D, Watanabe T, Shimada T. Basal medium development for serum-free culture: a historical perspective. Cytotechnology. 1997;23:95-101.
60. Nyberg G, Balcarcel R, Follstad B, Stephanopoulos G, Wang D. Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells. Biotechnol Bioeng. 1999;62:336-347.
61. Chapman A, Calhoun J. Effects of glucose starvation and puromycin treatment on lipid-linked oligosaccharide precursors and biosynthetic enzymes in Chinese hamster ovary cells in vivo and in vitro. Arch Biochem Biophys. 1988;260:320-333.
62. Liu B, Spearman M, Doering J, Lattová E, Perreault H, Butler M. The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody. J Biotechnol. 2014;170:17-27.
63. Seo Jk Min B, Kim Y, et al. Effect of glucose feeding on the glycosylation quality of antibody produced by a human cell line, f2n78, in fed-batch culture. Appl Microbiol Biotechnol. 2014;98:3509-3515.
64. Cruz H, Peixoto C, Nimtz M, et al. Metabolic shifts do not influence the glycosylation patterns of a recombinant fusion protein expressed in BHK cells. Biotechnol Bioeng. 2000;69:129-139.
65. Hayter P, Curling E, Baines A, et al. Glucose-limited chemostat culture of Chinese hamster ovary cells producing recombinant human interferon-gamma. Biotechnol Bioeng. 1992;39:327-335.
66. Wong NS, Wati L, Nissom P, Feng H, Lee M, Yap M. An investigation of intracellular glycosylation activities in CHO cells: effects of nucleotide sugar precursor feeding. Biotechnol Bioeng. 2010;107:321-336.
67. Kayakiri H, Takase S, Shibata T, et al. Structure of kifunensine, a new immunomodulator isolated from an actinomycete. J Org Chem. 1989;54:4015-4016.
68. Elbein A, Tropea J, Mitchell M, Kaushal G. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J Biol Chem. 1990;265:15599-15605.
69. Liebminger E, Hüttner S, Vavra U, et al. Class I alpha-mannosidases are required for N-glycan processing and root development in arabidopsis thaliana. Plant Cell. 2009;21:3850-3867.
70. Butters T, Alonzi D, Kukushkin N, Ren Y, Blériot Y. Novel mannosidase inhibitors probe glycoprotein degradation pathways in cells. Glycoconjug J. 2009;26:1109-1116.
71. Zhou Q, Shankara S, Roy A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99:652-665.
72. Shi H, Goudar C. Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans. Biotechnol Bioeng. 2014;111:1907-1919.
73. Kato A, Kato N, Kano E, et al. Biological properties of D- and L-1-deoxyazasugars. J Med Chem. 2005;48:2036-2044.
74. Shashidhara K, Gaikwad S, Khan M, Bharadwaj K, Pandey G. Interaction of α-mannosidase from aspergillus fischeri with glycosidase inhibitors, metal ions and group specific reagents. Res J Biotechnol. 2009;4:39-48.
75. Vidyasagar A, Sureshan K. Total synthesis and glycosidase inhibition studies of (-)-gabosine J and its derivatives. Eur J Org Chem. 2014;2014:2349-2356.
76. Kato A, Wang L, Ishii K, Seino J, Asano N, Suzuki T. Calystegine b3 as a specific inhibitor for cytoplasmic alpha-mannosidase, man2c1. J Biochem. 2011;149:415-422.
77. Gholamhoseinian A, Fallah H, Sharifi-Far F, Mirtajaddini M. Alpha mannosidase inhibitory effect of some iranian plant extracts. Int J Pharmacol. 2008;4:460-465.
78. Zhu Y, Suits MD, Thompson A, et al. Mechanistic insights into a Ca2+-dependent family of alpha-mannosidases in a human gut symbiont. Nat Chem Biol. 2010;6:125-132.
79. Williams R, Iglesias-Fernández J, Stepper J, et al. Combined inhibitor free-energy landscape and structural analysis reports on the mannosidase conformational coordinate. Angew Chem. 2014;53:1087-1091.
80. Aoyagi Ti Yamamoto T, Kojiri K, et al. Mannostatins A and B: new inhibitors of alpha-D-mannosidase, produced by streptoverticillium verticillus var. Quintum ME3-ag3: taxonomy, production, isolation, physico-chemical properties and biological activities. J Antibiotics. 1989;42:883-889.
81. Kuntz D, Zhong W, Guo J, Rose D, Boons G. The molecular basis of inhibition of golgi alpha-mannosidase II by mannostatin a. Chembiochem. 2009;10:268-277.
82. Petersen L, Ardèvol A, Rovira C, Reilly P. Molecular mechanism of the glycosylation step catalyzed by golgi alpha-mannosidase II: a QM/MM metadynamics investigation. J Am Chem Soc. 2010;132:8291-8300.
83. Retamal C, Dias A, Brasil F, Lanzana F, López M. Alpha-mannosidase activity in stallion epididymal fluid and spermatozoa. Theriogenology. 2012;78:252-262.
84. Asano N, Nash R, Molyneux R, Fleet G. Sugar-mimic glycosidase inhibitors: natural occurrence, biological activity and prospects for therapeutic application. Tetrahedron. 2000;11:1645-1680.
85. Siadak T, Espling E, Mcgourty J, et al. Enhancing Biological Activity of Immunoglycoproteins by a Convenient Method of Generating Preferred Glycovariants. Poster presentation at Cell Culture Engineering XI, April 13-18, 2008.
86. St Amand M, Radhakrishnan D, Robinson A, Ogunnaike B. Identification of manipulated variables for a glycosylation control strategy. Biotechnol Bioeng. 2014;111:1957-1970.
87. Surve T, Gadgil M. Manganese increases high mannose glycoform on monoclonal antibody expressed in CHO when glucose is absent or limiting: implications for use of alternate sugars. Biotechnol Prog. 2014:1-28.
88. Hossler P, McDermott S, Racicot C, et al. Cell culture media supplementation of uncommonly used sugars sucrose and tagatose for the targeted shifting of protein glycosylation profiles of recombinant protein therapeutics. Biotechnol Prog. 2014:20-24.
89. Tu Z, Lin Y, Lin C. Development of fucosyltransferase and fucosidase inhibitors. Chem Soc Rev. 2013;42:4459-4475.
90. Rillahan C, Antonopoulos A, Lefort C, et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol. 2012;8:661-668.
91. Kamiska J, Dziecio J, Kościelak J. Triazine dyes as inhibitors and affinity ligands of glycosyltransferases. Glycoconjug J. 1999;16:719-723.
92. Hosoguchi K, Maeda T, Furukawa J, et al. An efficient approach to the discovery of potent inhibitors against glycosyltransferases. J Med Chem. 2010;53:5607-5619.
93. Niu X, Fan X, Sun J, Ting P, Narula S, Lundell D. Inhibition of fucosyltransferase VII by gallic acid and its derivatives. Arch Biochem Biophys. 2004;425:51-57.
94. Burleigh S, Laar T, Stroop C, et al. Synergizing metabolic flux analysis and nucleotide sugar metabolism to understand the control of glycosylation of recombinant protein in CHO cells. BMC Biotechnol. 2011;11:95
95. Kötzler M, Blank S, Bantleon F, Wienke M, Spillner E, Meyer B. Donor assists acceptor binding and catalysis of human α1, 6-fucosyltransferase. ACS Chem Biol. 2013;8:1830-1840.
96. Galan M, Venot A, Boons G. Glycosyltransferase activity can be modulated by small conformational changes of acceptor substrates. Biochemistry. 2003;42:8522-8529.
97. Crispin M, Harvey D, Chang V, et al. Inhibition of hybrid- and complex-type glycosylation reveals the presence of the GlcNAc transferase I-independent fucosylation pathway. Glycobiology. 2006;16:748-756.
98. Grainger R, James D. CHO cell line specific prediction and control of recombinant monoclonal antibody N-glycosylation. Biotechnol Bioeng. 2013;110:2970-2983.
99. Hills A, Patel A, Boyd P, James D. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells. Biotechnol Bioeng. 2001;75:239-251.
100. McCracken N, Kowle R, Ouyang A. Control of galactosylated glycoforms distribution in cell culture system. Biotechnol Prog. 2014;30:547-553.
101. Gao Y, Lazar C, Szarek W, Brockhausen I. Specificity of β1, 4-galactosyltransferase inhibition by 2-naphthyl 2-butanamido-2-deoxy-1-thio-β-D-glucopyranoside. Glycoconjug J. 2010;27:673-684.
102. Chen P, Harcum S. Effects of elevated ammonium on glycosylation gene expression in CHO cells. Metab Eng. 2006;8:123-132.
103. Descroix K, Wagner G. The first C-glycosidic analogue of a novel galactosyltransferase inhibitor. Org Biomol Chem. 2011;9:1855-1863.
104. Descroix K, Pesnot T, Yoshimura Y, et al. Inhibition of galactosyltransferases by a novel class of donor analogues. J Med Chem. 2012;55:2015-2024.
105. Brown J, Yang F, Sinha A, et al. Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. J Biol Chem. 2009;284:4952-4959.
106. Mitsuhashi Ni Yuasa H. A novel galactosyltransferase inhibitor with diamino sugar as a pyrophosphate mimic. Eur J Org Chem. 2009;2009:1598-1605.
107. Gao Y, Vlahakis J, Szarek W, Brockhausen I. Selective inhibition of glycosyltransferases by bivalent imidazolium salts. Bioorg Med Chem. 2013;21:1305-1311.
108. Hayashi T, Murray B, Wang R, Wong C. A chemoenzymatic synthesis of UDP-(2-deoxy-2-fluoro)-galactose and evaluation of its interaction with galactosyltransferase. Bioorg Med Chem. 1997;5:497-500.
109. Gu X, Wang D. Improvement of interferon-gamma sialylation in chinese hamster ovary cell culture by feeding of N-acetylmannosamine. Biotechnol Bioeng. 1998;58:642-648.
110. Baker K, Rendall M, Hills A, Hoare M, Freedman R, James D. Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol Bioeng. 2001;73:188-202.
111. Bork K, Reutter W, Weidemann W, Horstkorte R. Enhanced sialylation of EPO by overexpression of UDP-GlcNAc 2-epimerase/ManAc kinase containing a sialuria mutation in CHO cells. FEBS Lett. 2007;581:4195-4198.
112. Bork K, Horstkorte R, Weidemann W. Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci. 2009;98:3499-3508.
113. Jones M, Teng H, Rhee J, Lahar N, Baskaran G, Yarema K. Characterization of the cellular uptake and metabolic conversion of acetylated N-acetylmannosamine (ManNAc) analogues to sialic acids. Biotechnol Bioeng. 2004;85:394-405.
114. Rodriguez J, Spearman M, Huzel N, Butler M. Enhanced production of monomeric interferon-beta by CHO cells through the control of culture conditions. Biotechnol Prog. 2005;21:22-30.
115. Yang M, Butler M. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog. 2002;18:129-138.
116. Magesh S, Savita V, Moriya So, et al. Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids. Bioorg Med Chem. 2009;17:4595-4603.
117. Ha T, Kim Y, Lee G. Effect of lithium chloride on the production and sialylation of Fc-fusion protein in Chinese hamster ovary cell culture. Appl Microbiol Biotechnol. 2014;98:9239-9248.
118. Viktorínová A, Toserová E, Krizko M, Duracková Z. Altered metabolism of copper, zinc, and magnesium is associated with increased levels of glycated hemoglobin in patients with diabetes mellitus. Metab Clin Exp. 2009;58:1477-1482.
119. Mikulíková K, Eckhardt A, Kunes J, Zicha J, Miksík I. Advanced glycation end-product pentosidine accumulates in various tissues of rats with high fructose intake. Physiol Res. 2008;57:89-94.
120. Han J, Tan C, Wang Y, Yang S, Tan D. Betanin reduces the accumulation and cross-links of collagen in high-fructose-fed rat heart through inhibiting non-enzymatic glycation. Chem-Biol Interact. 2015;227C:37-44.
121. Wu C, Huang S, Lin J, Yen G. Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct. 2011;2:224-234.
122. Gaza-Bulseco G, Li B, Bulseco A, Liu H. Method to differentiate asn deamidation that occurred prior to and during sample preparation of a monoclonal antibody. Anal Chem. 2008;80:9491-9498.
123. Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by Charge-sensitive methods. Curr Pharm Biotechnol. 2008;9:468-481.
124. Yang H, Zubarev R. Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis. 2010;31:1764-1772.
125. Pace A, Wong R, Zhang Y, Kao Y, Wang Y. Asparagine deamidation dependence on buffer type, pH, and temperature. J Pharm Sci. 2013;102:1712-1723.
126. Stratton L, Kelly R, Rowe J, et al. Controlling deamidation rates in a model peptide: effects of temperature, peptide concentration, and additives. J Pharm Sci. 2001;90:2141-2148.
127. Wakankar A, Borchardt R. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci. 2006;95:2321-2336.
128. Ji J, Zhang B, Cheng W, Wang Y. Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization. J Pharm Sci. 2009;98:4485-4500.
129. Bergès J, Trouillas P, Houée-Levin C. Oxidation of protein tyrosine or methionine residues: from the amino acid to the peptide. J Phys Conf Ser. 2011;261:012003
130. Li S, Schöneich C, Borchardt R. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. 1995;48:490-500.
131. Dick L, Qiu D, Mahon D, Adamo M, Cheng K. Cterminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol Bioeng. 2008;100:1132-1143.
132. Xu W, Peng Y, Wang F, Paporello B, Richardson D, Liu H. Method to convert N-terminal glutamine to pyroglutamate for characterization of recombinant monoclonal antibodies. Anal Biochem. 2013;436:10-12.
133. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310-312.
134. Johnson K, Paisley-Flango K, Tangarone B, Porter T, Rouse J. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem. 2007;360:75-83.
135. Kaschak T, Boyd D, Lu F, et al. Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media. mAbs. 2011;3:577-583.
136. Yuk I, Russell S, Tang Y, et al. Effects of copper on CHO cells: cellular requirements and product quality considerations. Biotechnol Prog. 2014:1-13.
137. Vijayasankaran N, Varma S, Yang Y, et al. Effect of cell culture medium components on color of formulated monoclonal antibody drug substance. Biotechnol Prog. 2013;29:1270-1277.
138. Chumsae C, Gifford K, Lian W, Liu H, Radziejewski C, Zhou Z. Arginine modifications by methylglyoxal: discovery in a recombinant monoclonal antibody and contribution to acidic species. Anal Chem. 2013;85:11401-11409.
139. Vázquez-Rey M, Lang D. Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng. 2011;108:1494-1508.
140. Paul A, Schwab K, Hesse F. Direct analysis of mAb aggregates in mammalian cell culture supernatant. BMC Biotechnol. 2014;14:99
141. Zhang Y, Howitt J, McCorkle S, Lawrence P, Springer K, Freimuth P. Protein aggregation during overexpression limited by peptide extensions with large net negative charge. Prot Exp Purif. 2004;36:207-216.
142. Spearman M, Rodriguez J, Huzel N, Sunley K. Effect of Culture Conditions on Glycosylation of Recombinant beta-Interferon in CHO Cells. Cell Technol Cell Product 2007:71-85.
143. Ju H, Hwang S, Jeon C, Lee G, Yoon S. Use of NaCl prevents aggregation of recombinant COMP-angiopoietin-1 in Chinese hamster ovary cells. J Biotechnol. 2009;143:145-150.
144. Brown C, Hong-Brown L, Biwersi J, Verkman A, Welch W. Chemical chaperones correct the mutant phenotype of the delta f508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones. 1996;1:117-125.
145. Zhou S, Zhang B, Sturm E, et al. Comparative evaluation of disodium edetate and diethylenetriaminepentaacetic acid as iron chelators to prevent metal-catalyzed destabilization of a therapeutic monoclonal antibody. J f Pharm Sci. 2010;99:4239-4250.
146. Mahler H, Friess W, Grauschopf U, Kiese S. Protein aggregation: pathways, induction factors and analysis. J Pharm Sci. 2009;98:2909-2934.
147. Hossler P, McDermott S, Racicot C, Fann J. Improvement of mammalian cell culture performance through surfactant enabled concentrated feed media. Biotechnol Prog. 2013;29:1023-1033.
148. Onitsuka M, Tatsuzawa M, Asano R, et al. Trehalose suppresses antibody aggregation during the culture of Chinese hamster ovary cells. J Biosci Bioeng. 2014;117:632-638.
149. Onitsuka M, Kawaguchi A, Asano R, et al. Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture. J Biosci Bioeng. 2014;117:639-644.
150. Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. mAbs. 2011;3:253-263.
151. Sandberg H, Lütkemeyer D, Kuprin S, et al. Mapping and partial characterization of proteases expressed by a CHO production cell line. Biotechnol Bioeng. 2006;95:961-971.
152. Robert F, Bierau H, Rossi M, et al. Degradation of an Fc-fusion recombinant protein by host cell proteases: identification of a CHO cathepsin D protease. Biotechnol Bioeng. 2009;104:1132-1141.
153. Gao S, Zhang Y, Stansberry-Perkins K, et al. Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. Biotechnol Bioeng. 2011;108:977-982.
154. Ouellette D, Alessandri L, Piparia R, et al. Elevated cleavage of human immunoglobulin gamma molecules containing a lambda light chain mediated by iron and histidine. Anal Biochem. 2009;389:107-117.
155. Kim K, Rhee S, Stadtman E. Nonenzymatic cleavage of proteins by reactive oxygen species generated by dithiothreitol and iron. J Biol Chem. 1985;260:15394-15397.
156. Chaderjian W, Chin E, Harris R, Etcheverry T. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog. 2005;21:550-553.
157. Kao Y, Hewitt D, Trexler-Schmidt M, Laird M. Mechanism of antibody reduction in cell culture production processes. Biotechnol Bioeng. 2010;107:622-632.
158. Cordoba A, Shyong Bn Breen D, Harris R. Non-enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr B. 2005;818:115-121.
159. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006;5:785-799.
160. Wen D, Vecchi M, Gu S, et al. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem. 2009;284:32686-32694.
161. Khetan A, Huang Y, Dolnikova J, et al. Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol Bioeng. 2010;107:116-123.
162. Zhang H, Wang H, Liu M, et al. Rational development of a serum-free medium and fed-batch process for a GS-CHO cell line expressing recombinant antibody. Cytotechnology. 2013;65:363-378.
163. Galewitz H, editor. Music-A Book of Quotations. Mineaola: Dover Publications, Inc.; 2001.